Tarsus Pharmaceuticals, Inc. (TARS)

Market Cap	2.90B
Revenue (ttm)	366.10M
Net Income (ttm)	-81.16M
Shares Out	42.45M
EPS (ttm)	-1.99
PE Ratio	n/a
Forward PE	78.45
Dividend	n/a
Ex-Dividend Date	n/a

Volume	565,822
Open	67.81
Previous Close	68.09
Day's Range	65.93 - 69.25
52-Week Range	38.51 - 76.81
Beta	0.76
Analysts	Strong Buy
Price Target	69.86 (+2.36%)
Earnings Date	Nov 4, 2025

About TARS

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company’s lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company devel...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 323
• Stock Exchange: NASDAQ
• Ticker Symbol: TARS
• Website: https://www.tarsusrx.com

Financial Performance

In 2024, Tarsus Pharmaceuticals's revenue was $182.95 million, an increase of 948.62% compared to the previous year's $17.45 million. Losses were -$115.55 million, -14.97% less than in 2023.

Analyst Summary

According to 7 analysts, the average rating for TARS stock is "Strong Buy." The 12-month stock price target is $69.86, which is an increase of 2.36% from the latest price.

Price Target

$69.86

(2.36% upside)

Analyst Consensus: Strong Buy